2 stocks that could be slammed by Donald Trump

Donald Trump’s policies are looking like very bad news for these two UK companies.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Donald Trump has undoubtedly been a net positive for equities in the US. The new president’s talk of lower taxes, lower regulation and an economic stimulus programme breathed new life into the shares of banks, energy producers and builders alike. But on this side of the Atlantic I have my fears that Trump’s bombastic attacks on certain industries leaves several UK stocks in danger of being hugely negatively affected by his potential policies.

First up is speciality drug producer Shire (LSE: SHP). What worries me about Trump and Shire is that the he’s been quoted in the press as saying things such as “the pricing has been astronomical” and “you folks [drug companies] have done a very great job over the years but we have to get the prices down.

And Trump could definitely do something about bringing down drug prices either through direct legislation or giving government-run medical programmes the ability to negotiate their prices with drug makers. This is a common sense move that has somehow escaped Congress’s attention thus far.

This is a problem for all drug makers but is an extra worry for Shire as the company’s business model is based on developing drugs for rare diseases and then charging very, very high prices for the treatment.

Aside from concerns that its products may fetch lower prices, I’m also worried because Shire has taken on a whopping $23bn in net debt to fund a series of huge acquisitions that have made it a world leader in rare disease treatments. If the company’s ambitious sales and profit targets are met this won’t be a major problem, but should Trump take an axe to pharmaceutical prices, it certainly would be.

Rough seas ahead for global trade?

Also at risk of becoming collateral damage to Trump’s policies is ship broker Clarkson (LSE: CKN). It has already seen profits drop in the past year as a slowdown in demand for oil & gas-related ships and an oversupply of cargo vessels have led to low prices for bulk shipping.

The threat from Trump to Clarkson is if the new president embarks on his much-talked-about plan to impose tariffs on trading partners such as Mexico or, more worryingly, China. Were Trump to slap import taxes on goods from China, the Chinese would undoubtedly retaliate, threatening to send the volume of trade between these important partners plummeting.

This would be a problem for Clarkson because its broking services account for more than 85% of underlying pre-tax profits and would be negatively impacted should volumes and the price of cargo shipping fall.

The upside is that as a broker, Clarkson doesn’t own any ships and is paid a commission per deal arranged, so is somewhat protected from any downturn. Indeed, the company has weathered problems in the offshore oil & gas industry with aplomb and remains solidly profitable and has a cash-heavy balance sheet.

But with shares of the company trading hands at a lofty 25 times forward earnings would-be investors would do well to image the potential threat from Trump’s policies before buying shares.

Are you looking for Trump-resistant shares?

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Looking for a £750 monthly passive income? Here’s how much it takes

The idea of buying dividend shares for their passive income potential can sound promising. How might the nuts and bolts…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

£20,000 in this ISA portfolio would generate £1,400 in passive income

Ben McPoland presents a ready-made Stocks and Shares ISA portfolio containing five UK names that as a group currently yield…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The most underrated stock in the FTSE 100?

Nobody seems to like the FTSE 100’s water utilities. But could Severn Trent be the biggest opportunity that investors aren’t…

Read more »

a couple embrace in front of their new home
Investing Articles

£1,000 now buys 1,075 Taylor Wimpey shares. Worth it for the 8% dividend yield?

There’s a massive dividend yield on offer from his well-known UK housebuilder right now. But what are the risks for…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

Want to invest in SpaceX, Revolut, and TikTok? Consider buying this FTSE 100 stock

Ben McPoland thinks this FTSE 100 investment trust is a top stock to consider buying to gain exposure to the…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s my Stocks and Shares ISA plan for 2026/27

Stephen Wright has a clear plan when it comes to investing in his Stocks and Shares ISA. But do the…

Read more »

Two elderly people relaxing in the summer sunshine Box Hill near Dorking Surrey England
Investing Articles

Where to look for safety in today’s stock market?

Stephen Wright has been looking for safety in a specific place in today’s stock market. And Warren Buffett’s firm has…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

This 5-share ISA could deliver an amazing second income of £762 a month

As the world’s stock markets plunge, many yields are rising. James Beard looks at five shares that could generate an…

Read more »